Jonathan Wolfson is the Chief Executive Officer and co-founder of Solazyme, where he oversees the management and strategic direction of the company. Prior to Solazyme, Mr. Wolfson held a variety of positions in finance, business and law. He was most recently the Vice President of Finance and Business Development for 7thOnline, a venture-backed supply chain software company where he was responsible for overseeing partnering, finance and the development and implementation of corporate strategy, which resulted in annualized revenue growth of over 100% during his tenure.

Prior to that, Mr. Wolfson was co-founder, President and Chief Operating Officer of InvestorTree, a financial software and services firm. He has also worked as an investment banker for Morgan Stanley and as a business/legal analyst for Triarc Companies.

Beyond his responsibilities for Solazyme, Mr. Wolfson is dedicated to enabling the adoption of a low carbon energy future. He sits on the board of the Clean Economy Network, a green business advocacy association. He provides additional insight as an advisory board member to the Next Generation Bio-Based Chemicals Summit, a cross-sector of oil and alternative fuel resources. In addition, Mr. Wolfson is a member of the board of directors of the Biotechnology Industry Organization (BIO) and is on the governing board of BIO’s Industrial and Environmental Section. In September of 2009, Mr. Wolfson also accepted the “Green Leap” award from the Clinton Global Initiative for his commitment to commercializing Solazyme’s breakthrough technology for renewable oil production for fuel and for food. It is through these commitments and board memberships that Mr. Wolfson furthers the evolution of the advanced biofuels and biomaterials industries and continues his commitment to clean, renewable energy and carbon pollution reduction.

Mr. Wolfson holds J.D. and M.B.A. degrees from the NYU School of Law and the NYU Stern School of Business. Additionally, he spent several years as an Adjunct Assistant Professor of Economics at Hunter College of the City University of New York.

Tyler Painter is the Chief Financial Officer of Solazyme. Most recently, Mr. Painter acted as interim Vice President of Finance and Corporate Controller for PMC-Sierra (PMCS), a leading provider of broadband communications and storage semiconductors, where he was instrumental in managing the finance organization through a period of significant transition while bolstering financial controls.

Prior to PMC-Sierra, Mr. Painter spent over six years at Wind River Systems (WIND), a publicly traded billion-dollar device software company, as VP of Finance responsible for Treasury, Tax and Investor Relations. While at Wind River, he earned several national awards for implementing industry-leading approaches to finance operations, including the Association of Finance Professional’s 2006 Pinnacle Award for Risk Management and the 2007 Top 5 Best Corporate Governance Practices in the U.S, awarded by Investor Relations Global Rankings.

Before Wind River, Mr. Painter was a key member of the management team at Carsdirect, growing the company from pre-revenue to $150 million in revenue in two years and raising over $300 million in private equity. Earlier in his career, Mr. Painter held various finance roles at Gap, Inc.

Mr. Painter brings 16 years of financial and operational management experience across private, public and Fortune 500 companies to Solazyme. He earned his Bachelor of Science degree in Finance from California Polytechnic University, San Luis Obispo. He is actively involved with a number of professional affiliations including the Association of Financial Professionals and the National Investor Relations Institute.

Peter Licari is the Senior Vice President of Research and Development at Solazyme. Dr. Licari has over 20 years experience in biochemical engineering and bioprocessing, most recently as a Senior Vice President at Kosan Biosciences, Inc. where his responsibilities included development and manufacturing operations from 1998 - 2008. Before joining Kosan, Dr. Licari was Director of Vaccine Manufacturing and Development at Massachusetts Biologic Laboratories. From 1993 to 1996, Dr. Licari served as Senior Scientist at BASF Bioresearch Corporation, responsible for fermentation process development. After receiving his Ph.D. in Chemical Engineering with a Minor in Biology from the California Institute of Technology in 1992, he joined Merck as an Engineering Associate. In 2005 he obtained an M.B.A. degree from Pepperdine University.

David Isaacs is the Senior Vice President of Government Relations of Solazyme, responsible for formulating and executing the company’s government strategy at the federal and state level. In this capacity he is working to advance the company’s priorities on funding opportunities, legislation, regulatory matters, and policy, particularly with regard to the Congress, the Departments of Defense and Energy, the Environmental Protection Agency, and key states.

Prior to joining Solazyme, Mr. Isaacs was Director of Government Relations for Hewlett-Packard Company and led the company’s office in Washington, D.C. At HP, he was responsible for directing the company's policy development, advocacy, and political programs before the Congress and the Executive Branch on a broad range of issues, including environment, energy and climate, technology policy, government procurement, intellectual property, tax, and trade. Mr. Isaacs previously worked on environmental policy for a national association of the information technology industry and practiced environmental law in Washington, D.C.

Mr. Isaacs received a B.A. from Tufts University and a J.D. from Columbia University School of Law.

Michael Golembieski is the Senior Vice President and General Manager of Nutritionals for Solazyme. Mr. Golembieski is responsible for building a global food and feed ingredient business for Solazyme’s renewable oils, purified microalgae, and microalgae extracts. Prior to joining Solazyme he served as Vice President of Global Strategy and Business Development for the SPLENDA® Sucralose ingredient division of Tate & Lyle, a $5.5 billon manufacturer and marketer of renewable food and industrial ingredients. In that role, Mr. Golembieski had broad responsibility for developing strategy and identifying growth opportunities in support of Tate & Lyle’s high performance sweetener platform. He was engaged in all aspects of business strategy and implementation for the business including pricing, market development, IP protection, and manufacturing platform optimization.

Mr. Golembieski has more than three decades of experience in finance, business, and strategy development in the food, biotechnology, and pharmaceutical industries, including a twenty one year career with Mallinckrodt’s medical imaging and respiratory products businesses as well as several years with Apath LLC, an early-stage biotechnology firm engaged in antiviral technology licensing and drug discovery.

Mr. Golembieski holds a degree in Business Administration from the University of Missouri/St. Louis, and is a certified public accountant.